Canopy Growth signs deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 92%

Business News News

Business Business Latest News,Business Business Headlines

Under the agreement, Canopy will receive an upfront payment of $115.5-million. The deal, which requires regulatory approvals, is expected to close by Jan. 31, 2022

says it has signed a deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary to German company Dermapharm Holding SE.It will also receive up an additional $61.4-million, subject to the achievement of certain milestones by the business.

The business being sold develops and manufactures pharmaceutical products and includes Spectrum Therapeutics GmbH, THC Pharm GmbH The Health Concept and Spectrum Therapeutics Austria GmbH.Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 5. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines